These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23687786)

  • 21. Targeted therapy for HER2 positive breast cancer.
    Incorvati JA; Shah S; Mu Y; Lu J
    J Hematol Oncol; 2013 Jun; 6():38. PubMed ID: 23731980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the HER2 receptor in metastatic breast cancer.
    Orphanos G; Kountourakis P
    Hematol Oncol Stem Cell Ther; 2012; 5(3):127-37. PubMed ID: 23095788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.
    Soleja M; Rimawi MF
    Curr Probl Cancer; 2016; 40(2-4):117-129. PubMed ID: 27839746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):4. PubMed ID: 19364050
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Targeted therapy and breast cancer: state of the art].
    Molnar-Stanciu D; Guimas V; Bensalem A; Thiery-Vuillemin A
    Pathol Biol (Paris); 2012 Aug; 60(4):254-63. PubMed ID: 22728007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to Anti-HER2 Therapies in Breast Cancer.
    Rimawi MF; De Angelis C; Schiff R
    Am Soc Clin Oncol Educ Book; 2015; ():e157-64. PubMed ID: 25993167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 33. Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient.
    Freedman RA; Muss HB
    J Geriatr Oncol; 2014 Jan; 5(1):2-7. PubMed ID: 24484711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fifteen years of anti-HER2 therapy.
    Davidson NE
    Oncology (Williston Park); 2013 Mar; 27(3):151. PubMed ID: 23687781
    [No Abstract]   [Full Text] [Related]  

  • 35. Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.
    Wilcken N; Zdenkowski N; White M; Snyder R; Pittman K; Mainwaring P; Green M; Francis P; De Boer R; Colosimo M; Chua S; Chirgwin J; Beith J; Bell R
    Asia Pac J Clin Oncol; 2014 Jun; 10 Suppl S4():1-14. PubMed ID: 24797445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-Her2 therapy in breast cancer].
    Kuroi K
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():606-13. PubMed ID: 23350472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.